Physician profile
Josh Levitsky
NPI 1770573305
$264,525.10
in general payments reported to CMS, 2019-2025
15 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73K · 2020: $35K · 2021: $25K · 2022: $39K · 2023: $33K · 2024: $59K · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Travel and Lodging: $8,445 · Consulting Fee: $5,580 · Food and Beverage: $1,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,481.27 |
| Travel and Lodging | $8,444.89 |
| Consulting Fee | $5,580.00 |
| Food and Beverage | $1,797.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $111,085.24 | 2020-2025 | Terlivaz |
| Gilead Sciences, INC. | $47,633.00 | 2019-2024 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $38,291.95 | 2023-2024 | Livtencity |
| Novartis Pharmaceuticals Corporation | $36,573.08 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $13,830.00 | 2019 | |
| Becton, Dickinson and Company | $5,670.26 | 2019 | |
| Dynavax Technologies Corporation | $3,750.00 | 2020 | |
| Novo Nordisk INC | $3,165.48 | 2022-2024 | |
| Saol Therapeutics INC. | $3,000.00 | 2020 | |
| Merck Sharp & Dohme LLC | $652.97 | 2023 | |
| Saol International Limited | $500.00 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $244.53 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.86 | 2022-2024 | Xifaxan |
| Madrigal Pharmaceuticals | $43.17 | 2024 | Resmetirom |
| Travere Therapeutics, INC. | $2.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josh Levitsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.